CA2273353C - Galenic composition containing opioid antagonists - Google Patents

Galenic composition containing opioid antagonists Download PDF

Info

Publication number
CA2273353C
CA2273353C CA2273353A CA2273353A CA2273353C CA 2273353 C CA2273353 C CA 2273353C CA 2273353 A CA2273353 A CA 2273353A CA 2273353 A CA2273353 A CA 2273353A CA 2273353 C CA2273353 C CA 2273353C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
oral pharmaceutical
composition according
particles
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2273353A
Other languages
English (en)
French (fr)
Other versions
CA2273353A1 (en
Inventor
Kersten Walter
Thomas Profitlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Deutschland GmbH
Original Assignee
Norgine Europe BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norgine Europe BV filed Critical Norgine Europe BV
Publication of CA2273353A1 publication Critical patent/CA2273353A1/en
Application granted granted Critical
Publication of CA2273353C publication Critical patent/CA2273353C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2273353A 1996-12-11 1997-12-04 Galenic composition containing opioid antagonists Expired - Fee Related CA2273353C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19651551A DE19651551C2 (de) 1996-12-11 1996-12-11 Opioidantagonisthaltige galenische Formulierung
DE19651551.3 1996-12-11
PCT/EP1997/006789 WO1998025613A2 (de) 1996-12-11 1997-12-04 Opioidantagonisthaltige galenische formulierung

Publications (2)

Publication Number Publication Date
CA2273353A1 CA2273353A1 (en) 1998-06-18
CA2273353C true CA2273353C (en) 2011-02-08

Family

ID=7814396

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2273353A Expired - Fee Related CA2273353C (en) 1996-12-11 1997-12-04 Galenic composition containing opioid antagonists

Country Status (10)

Country Link
US (1) US6419959B1 (https=)
EP (1) EP0938316B1 (https=)
JP (1) JP5065548B2 (https=)
AT (1) ATE220907T1 (https=)
CA (1) CA2273353C (https=)
DE (2) DE19651551C2 (https=)
DK (1) DK0938316T3 (https=)
ES (1) ES2181055T3 (https=)
PT (1) PT938316E (https=)
WO (1) WO1998025613A2 (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
EP1041987B1 (en) 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
CA2446738C (en) * 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
HUE032656T2 (en) * 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2013203378B2 (en) * 2003-04-08 2016-09-15 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
RU2005134364A (ru) * 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
HRP20150037T4 (hr) * 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
EP2905033B1 (en) * 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
AU2006206454A1 (en) * 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
EP2214672B1 (en) * 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2729582C (en) 2008-07-01 2017-09-19 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9056054B2 (en) 2009-06-25 2015-06-16 Elite Laboratories, Inc. Abuse resistant oral dosage forms
UA123856C2 (uk) 2010-03-11 2021-06-16 Уайт Елелсі Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
AU2011252039B2 (en) 2010-05-10 2014-06-12 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015086528A1 (de) 2013-12-11 2015-06-18 Develco Pharma Schweiz Ag Naloxon-monopräparat und mehrschichttablette
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20160256452A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time
US20160256451A1 (en) 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
EP3290027A1 (en) 2016-09-02 2018-03-07 Develco Pharma Schweiz AG Method and composition for the treatment of opioid induced constipation
BR112021022194A2 (pt) 2019-05-07 2021-12-28 Bausch Health Ireland Ltd Formulações líquidas para dosagem oral de metilnaltrexona

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
EP0103636B1 (en) 1982-03-16 1990-09-12 Rockefeller University Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility
US4774230A (en) 1988-03-26 1988-09-27 Ivax Laboratories, Inc. Glucuronic acid derivatives of opioid antagonists
EP0352361A1 (en) * 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
EP0914097B1 (en) * 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist

Also Published As

Publication number Publication date
WO1998025613A2 (de) 1998-06-18
DE19651551C2 (de) 2000-02-03
DE19651551A1 (de) 1998-06-18
ATE220907T1 (de) 2002-08-15
ES2181055T3 (es) 2003-02-16
US6419959B1 (en) 2002-07-16
WO1998025613A3 (de) 1998-10-29
CA2273353A1 (en) 1998-06-18
EP0938316A2 (de) 1999-09-01
JP5065548B2 (ja) 2012-11-07
DE59707812D1 (de) 2002-08-29
EP0938316B1 (de) 2002-07-24
DK0938316T3 (da) 2002-10-21
PT938316E (pt) 2002-12-31
JP2001505897A (ja) 2001-05-08

Similar Documents

Publication Publication Date Title
CA2273353C (en) Galenic composition containing opioid antagonists
CA2541371C (en) Extended release formulations of opioids and method of use thereof
US8703186B2 (en) Abuse-resistant oral dosage forms and method of use thereof
US20040110781A1 (en) Pharmaceutical compositions containing indistinguishable drug components
JP4425093B2 (ja) 血漿中の薬物レベルの初期上昇速度が急速な２４時間経口オピオイド製剤の投与による、疼痛の治療方法
KR101467506B1 (ko) 오용 방지계를 포함하는 경구 제형
US11045422B2 (en) Abuse resistant drugs, method of use and method of making
US20090041838A1 (en) Anti-Misuse Microparticulate Oral Drug Form
AU1044701A (en) Composition for treatment of constipation and irritable bowel syndrome
HU218673B (hu) Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
JPH072635B2 (ja) 新規医薬製剤およびその製造方法
US20140037721A1 (en) Pharmaceutical Composition
AU2008296905A1 (en) A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
AU2008346870A1 (en) Pharmaceutical composition
JP2004512298A (ja) 遅延及び持続放出製剤、及びそれを使用する方法
AU2008338439A1 (en) Pharmaceutical composition
AU2014216032B2 (en) Pharmaceutical composition
JP2020524697A (ja) 乱用抑止経口固体投与形態
HK40016624A (en) Novel dosage form
AU2016225887A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141204